Results of the study OSTEOTENOFOVIR, about the effect that a change in the treatment has on bone mineral density, have been published.28/08/2014
Journal of Antimicrobial Chemotherapy, a major scientific publication of the University of Oxford, has published the results of the study OSTEOTENOFOVIR, a multicenter study (conducted in collaboration with patients at the Germans Trias i Pujol University Hospital and the Santa Creu i Sant Pau Hospital) to assess whether the change of tenofovir (an antiretroviral drug involved in the loss of bone) to abacavir improves bone mineral density, ie, the bone amount.
The aim of the study was to test the effect caused by this change in improving their osteoporosis or osteopenia, both characterized by low bone density, making bones fragile and susceptible to fractures. It is proven that people with HIV are at increased risk of these health complications and, moreover, a decrease in the amount of bone a few months after starting antiretroviral therapy, especially with tenofovir, has been observed.
Of the 54 patients participating in this study, 26 made the change from tenofovir to abacavir, and the rest continued treatment with tenofovir. They all made a first visit for a medical and analytical control, and after a year, they were tested again to assess changes that may have occurred in bone mineral density in the lumbar area and hips. Tests were performed by bone densitometry (DEXA), which is conducted with a device that emits very low X-rays doses.
According to the results, it is observed that the change of tenofovir to abacavir leads to a slight improvement in bone mineral density in these areas of the body, although larger studies will be needed before confirming recommendations regarding changes in treatment in patients with osteoporosis or osteopenia.